Type 2 diabetes
Drug research and approvals for type 2 diabetes: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 884 studies of type 2 diabetes are recruiting on ClinicalTrials.gov, Health Canada has authorized 148 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 41 authorised medicines for it.
- Recruiting worldwide: 884
- Trials authorized in Canada: 148
- FDA orphan approvals: 1
- EU medicines: 41
- EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary CareNCT07948928 · Not applicable · Montefiore Medical Center · starts Oct 28, 2026
- Home Visits and Telephone-Supported Education for Adults With Type 2 DiabetesNCT07949292 · Not applicable · Saglik Bilimleri Universitesi · starts Nov 10, 2026
- Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot WoundsNCT07937215 · Not applicable · Cutempa Medical AG · starts Aug 20, 2026
- Cardiopulmonary Exercise Active Health Cohort StudyNCT07935187 · Not reported · Peking University Third Hospital · starts May 11, 2026
- Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 DiabetesNCT07928661 · Phase 2 · Universitas Sriwijaya · starts Jul 29, 2026
- Ultrasound-Guided Thoracolumbar Fascia Injection for Chronic Low Back Pain in Patients With Type 2 DiabetesNCT07927530 · Not applicable · Hatice Zehra FERHATLAR · starts Oct 23, 2026
- Acute Blood Flow Restriction Walking on Immune Cell Phenotype and FunctionNCT07928531 · Not applicable · University of British Columbia · starts Feb 11, 2026
- Ocular Changes in Patients Using Tirzepatide or SemaglutideNCT07924618 · Not reported · Istanbul University · starts Mar 1, 2026
- Whole-Body Vibration Training in Women With Obesity With and Without Type 2 DiabetesNCT07924436 · Not applicable · Pamukkale University · starts Nov 9, 2026
How its trials ended
8,392 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 2,232 whose ending is known, 68% met their primary endpoint, 4% missed it and 28% stopped early.
- Completed, result not reported4,05148%
- Met its primary endpoint1,52118%
- Ongoing1,13714%
- Status unknown97212%
- Stopped: other or unclear3544%
- Stopped: enrollment or feasibility1141%
- Missed its primary endpoint921%
- Stopped: sponsor or business decision881%
- Stopped: lack of efficacy30<1%
- Stopped: funding20<1%
- Stopped: safety13<1%
| Aug 21, 2026 | Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at higher dose levels in participants with type 2 diabetes…Zenagamtide / Ozempic | Novo Nordisk | Ongoing |
| Aug 20, 2026 | A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of once weekly petrelintide vs. placebo in…Petrelintide (RO7895515) | Roche | Pending |
| Aug 18, 2026 | A phase 3, randomized, open-label trial comparing the efficacy and safety of maridebart cafraglutide once monthly versus semaglutide once weekly as add-on…Maridebart cafraglutide (amg 133) | Amgen | Ongoing |
| Aug 18, 2026 | A phase 3, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of maridebart cafraglutide versus placebo in participants with…Maridebart cafraglutide (amg 133) | Amgen | Pending |
| Aug 11, 2026 | Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased…Zenagamtide | Novo Nordisk | Ongoing |
| Aug 5, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of once-weekly eloralintide in adult participants with…Eloralintide (LY3841136) | Eli Lilly | Pending |
| Jul 23, 2026 | A phase III randomised, double-blind, placebo-controlled multicentre trial to evaluate the efficacy and safety of AZD6234 as an adjunct to incretin-based…Lenbelintide (AZD6234) | AstraZeneca Pharmaceuticals | Ongoing |
| Jul 23, 2026 | A phase III randomized, double-blind, placebo-controlled multicentre trial to evaluate the efficacy and safety of AZD6234 in participants with type 2 diabetes…Lenbelintide (AZD6234) | AstraZeneca Pharmaceuticals | Ongoing |
| Jun 24, 2026 | A phase 3, randomized, double-blind extension trial to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants…Maridebart cafraglutide (amg 133) | Amgen | Ongoing |
| Jun 11, 2026 | A phase III, randomised, double-blind, parallel-group, 56-week study, evaluating the efficacy and safety of survodutide (BI456906), compared with placebo, in…Survodutide (bi 456906) | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Feb 17, 2012 | KorlymFor the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2… | Corcept Therapeutics, Inc. | Approved |
| Jul 15, 2026 | Liraglutide STADALiraglutide | STADA Arzneimittel AG | EMA ↗ |
| Nov 24, 2025 | KyinsuInsulin icodec; semaglutide | Novo Nordisk A/S | EMA ↗ |
| Mar 31, 2023 | Sitagliptin / Metformin hydrochloride SunSitagliptin; metformin hydrochloride · generic | Sun Pharmaceutical Industries Europe B.V. | EMA ↗ |
| Mar 24, 2023 | Dapagliflozin ViatrisDapagliflozin · generic | Viatris Limited | EMA ↗ |
| Sep 15, 2022 | MounjaroTirzepatide | Eli Lilly Nederland B.V. | EMA ↗ |
| Apr 25, 2022 | Sitagliptin AccordSitagliptin · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Mar 24, 2022 | Vildagliptin / Metformin hydrochloride AccordVildagliptin; metformin hydrochloride · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 16, 2022 | Sitagliptin / Metformin hydrochloride MylanSitagliptin hydrochloride monohydrate; metformin hydrochloride · generic | Mylan Pharmaceuticals Limited | EMA ↗ |
| Feb 16, 2022 | KerendiaFinerenone | Bayer AG | EMA ↗ |
| Dec 9, 2021 | Sitagliptin SUNSitagliptin fumarate · generic | Sun Pharmaceutical Industries Europe B.V. | EMA ↗ |
| Apr 3, 2020 | RybelsusSemaglutide | Novo Nordisk A/S | EMA ↗ |
| Mar 23, 2018 | SteglujanErtugliflozin; sitagliptin | Merck Sharp & Dohme B.V. | EMA ↗ |
| Mar 23, 2018 | SeglurometErtugliflozin; metformin hydrochloride | Merck Sharp & Dohme B.V. | EMA ↗ |
| Mar 21, 2018 | SteglatroErtugliflozin | Merck Sharp & Dohme B.V. | EMA ↗ |
| Feb 8, 2018 | OzempicSemaglutide | Novo Nordisk A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA